Please assess the completion status of the following clinical trial:

Trial Title: Study of the Performance of the KeyPath MRSA/MSSA Blood Culture Test - BTA

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Blood culture samples determined to be Gram-positive from subjects aged 18+, inclusive, with any of the following bottle types:~   * bioMerieux BacT/ALERT® Standard Aerobic and Anaerobic~  * bioMerieux BacT/ALERT® FAN Aerobic and FAN Anaerobic~2. Completion of the KeyPathTM BTA Test on the sample.~3. Completion of the reference method for S. aureus identification (tube coagulase and Remel Staphaurex ) and completion of the reference method for methicillin resistance determination (30 µg cefoxitin disc diffusion) for S. aureus positive samples.~Exclusion Criteria:~1. Samples from blood culture positives over 24 hours from alarm~2. Samples deemed contaminated.~3. Violations and/or deviations from the KeyPathTM BTA Test protocol and/or other included test protocols under study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard of Care (Type: None): 1. Comparison of S. aureus to the reference methods for S. aureus (tube coagulase and Staphaurex.)~2. Comparison to the reference method (30 ug cefoxitin disc diffusion).
- KeyPath Test Group (Type: None): All specimens collected that meet the inclusion criteria will be tested using the KeyPath BTA Test.

Based on this trial design, predict the completion outcome and termination type (if applicable).